Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory a...( Board-Certified Regulatory Affair...)

Board-Certified Regulatory Affairs Professional Brings More Than Two

Decades of Pharmaceutical, Regulatory Agency and Research Experience

CINCINNATI, Feb. 1 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the hiring of Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality. Dr. Tripathi will provide additional leadership to the Regulatory Affairs Brand, overseeing the multi-functional global regulatory group consisting of approximately 450 personnel. He will focus on driving growth in the company's regulatory brand, which includes strategic clinical development planning, regulatory consulting and submissions, clinical trial regulatory affairs, nonclinical consulting, Chemistry, Manufacturing and Controls (CMC) development, medical writing and pharmacovigilance/safety services.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

"We are thrilled to have someone with Satish's background and experience as part of our regulatory leadership team," said Melanie Bruno, PhD, Vice President, Global Regulatory Affairs, Quality and Safety. "His ability to analyze the regulatory complexities of drug development and fashion a market positioning strategy to help ensure commercial success will provide a wonderful resource to Kendle's customers."

Dr. Tripathi served most recently as the Director of Worldwide Regulatory Strategy at Pfizer (formerly Pharmacia). Prior to that, he was a Director of Global Regulatory Affairs at the Biosciences Division of Baxter Healthcare Corporation in charge of all global regulatory submissions withi
'/>"/>